Good morning, HealthTech insiders. The next contest in HealthTech is taking place inside the workflow. A pathology platform has to work with the laboratory's scanners. An AI assistant has to bring useful information into the clinical encounter. A surgical robot has to fit the room and the team around it. Integration is becoming part of the product's value proposition, and today's announcements put three different approaches under the spotlight.
Agilent has agreed to buy Proscia in a deal worth up to $270 million. Suki has announced $90 million in Series E financing after launching Ask with UpToDate Expert AI. And J&J says it has signed OTTAVA's first commercial customer following July's FDA authorization. The direction is clear; the evidence for better care and lower costs still has to follow.
In today's Signal:
Agilent agrees to acquire Proscia for up to $270M: A pending deal combines pathology instruments and reagents with an open digital workflow platform.
Suki announces $90M Series E: Its recently launched Ask feature brings patient-chart context and UpToDate evidence into one clinician-facing interface.
OTTAVA signs its first commercial customer: J&J's October update marks early commercialization following FDA De Novo authorization in July.
Soufflé closes $135M Series B: Juvia Group leads financing to move cell-targeted RNA programs toward clinical studies.
In partnership with
7 Stocks Built to Hold Forever. See the Full List.
Chasing the next hot stock can be exhausting, and it rarely builds wealth the way investors expect. The strongest long-term portfolios are often anchored by durable, blue-chip businesses designed to withstand recessions, inflation and shifting market leadership.
MarketBeat’s free 7 Stocks to Buy and Hold Forever report identifies companies across technology, retail, consumer staples, healthcare, networking, sporting goods and utilities. Each offers its own mix of stability, income, growth and staying power.
These are not speculative names built around the latest headline. They are established businesses selected for investors who would rather own quality companies for years than constantly chase the market.
Get your complimentary copy and see all seven names today.
LATEST DEVELOPMENTS
COMMERCIAL M&A
1. Agilent Agrees to Acquire Proscia for Up to $270M
Digital pathology workflow imagery from Proscia. Credit: Proscia.
Agilent Technologies (NYSE: A) announced on October 13 that it has agreed to acquire Proscia for $240 million at closing and up to $30 million tied to future performance milestones. Closing remains subject to customary conditions and is expected early in Agilent's fiscal 2027.
The details:
Proscia's Concentriq platform connects slide images and laboratory workflows. Concentriq AP-Dx has FDA 510(k) clearance for primary diagnosis with specified compatible equipment. August's clearance added the Leica Aperio GT 450 DX scanner, cloud deployment and a Predetermined Change Control Plan; platform clearance does not automatically cover every connected AI algorithm.
The proposed combination builds on Agilent and Proscia's 2022 distribution partnership and could support biomarker research, companion diagnostics and clinical pathology workflows.
Agilent CEO Padraig McDonnell and Proscia co-founder and CEO David West describe a shared commitment to open, digital pathology. That direction matters to laboratories using equipment from several vendors, but future interoperability must be demonstrated in practice.
The Signal: The deal shows how valuable the workflow around an algorithm can become. Agilent could bring software closer to its pathology instruments, reagents and customers. For laboratories, the test is whether that integration improves everyday work while preserving equipment choice. It does not establish the end of independent pathology AI.
CLINICAL AI
2. Suki Announces $90M Series E After Ask Launch
Suki’s clinician-facing product interface. Credit: Suki.
Suki announced $90 million in financing as part of its Series E on October 13, backing its expansion across clinical, revenue-cycle and operational workflows.
The details:
New investors include Healthier Capital, Crosslink Capital and Hercules Capital, alongside existing institutional backers. Existing participants include Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures.
Suki reports serving more than 450 healthcare organizations and working with more than 30 technology partners. Its model combines a clinician-facing application with AI embedded in partner platforms.
Ask launched on October 8. It retrieves patient-specific information and synthesizes clinical content through Wolters Kluwer's UpToDate Expert AI. Suki explicitly describes it as an information retrieval and synthesis tool: it does not diagnose patients or prescribe treatment plans, and clinicians remain responsible for decisions.
The Signal: Bringing chart context and clinical evidence together could reduce the searching that interrupts an encounter. That is a useful expansion beyond documentation. The funding supports a broader ambition; it does not prove autonomous clinical reasoning, error-free answers or a guaranteed return on investment.
SURGICAL ROBOTICS
3. OTTAVA Signs Its First Commercial Customer
Johnson & Johnson’s table-integrated OTTAVA robotic surgical system. Credit: Johnson & Johnson
In its October 13 earnings update, Johnson & Johnson reported signing OTTAVA's first commercial customer. FDA De Novo authorization was granted on July 21 and announced on July 22, so this is a commercialization milestone rather than a new regulatory decision.
The details:
OTTAVA integrates four robotic arms into its operating table. J&J describes synchronized table-and-arm movement and a reduced footprint relative to traditional systems. The complete system still occupies space and requires installation and team training.
The authorization covers 10 specified general-surgery procedures, including gastric bypass, sleeve gastrectomy, cholecystectomy and hiatal hernia repair. It does not establish unrestricted multi-specialty use.
J&J says an inguinal-hernia IDE trial is underway and plans future development in urology and gynecology. Those expansion plans are distinct from the current authorized indications.
The Signal: OTTAVA brings a different physical architecture into commercial surgical robotics. Hospitals now need evidence about setup, access, training and case economics in their own operating rooms. A smaller footprint is a design advantage to evaluate; faster turnover and lower total costs remain outcomes to prove.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
Digital pathology interoperability: We are watching the Proscia deal's closing and whether laboratories retain validated scanner choices and third-party software integrations.
Ask's practical value: We are watching repeat clinician use, retrieval accuracy, source traceability and the time spent reviewing answers alongside the time saved searching.
OTTAVA's early commercial rollout: We are watching customer placements, training requirements and measured operating-room performance within the authorized indications.
💰 FOLLOW THE MONEY
The deals:
Soufflé Therapeutics ($135M Series B): Led by Juvia Group to advance REMEDY cell-targeted oligonucleotide programs toward clinical studies in muscular dystrophy, heart failure and muscle/metabolic disorders.
Suki ($90M Series E financing): New and existing investors support expansion of its healthcare AI products, integrations and partner ecosystem.
Brellium ($23M venture funding): Led by Left Lane Capital and First Round Capital, with Digital Health Venture Partners participating. CortexLM flags documentation and compliance issues before billing.: $70M Series C led by NewView Capital for ambient senior care AI at a $500M+ valuation.
The pattern: Investors are backing both tools that work within clinical workflows and platforms that connect several parts of care delivery. Suki and Brellium must translate product expansion into measurable use and value. Agilent must close and integrate its proposed acquisition, while J&J must build on OTTAVA's first customer. These are different stages of commercial progress, not interchangeable proof of clinical or financial success.
📆 UPCOMING HEALTHTECH EVENTS
Pathology Visions 2026 (October 16–18, Manchester Grand Hyatt, San Diego): Digital pathology implementation, clinical practice and AI.
Frontiers Health 2026 (October 20–21, bcc Berlin Congress Center, Berlin): Digital health, emerging technology and healthcare innovation.
HLTH USA 2026 (November 15–18, The Venetian Expo, Las Vegas): Healthcare innovation, investment and payer/provider collaboration.
🛠️ Trending HealthTech AI Tools
Suki Ask: Patient-chart information retrieval and UpToDate-based clinical evidence synthesis for clinician review.
CortexLM by Brellium: Pre-bill chart auditing that flags care and documentation issues against provider requirements.
Concentriq AP-Dx by Proscia: FDA-cleared digital pathology software for primary diagnosis with validated compatible equipment. Individual AI applications have their own regulatory scope.
🛠️ Trending HealthTech AI Startups
Soufflé Therapeutics: RNA therapeutics developer with a $135M Series B; its REMEDY platform targets delivery outside the liver.
Brellium: Clinical compliance and revenue-integrity AI platform with $23M in announced venture financing.
Suki: Ambient clinical intelligence company with newly announced Series E financing and a growing application and technology-partner business.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
What would most convince you to adopt a new HealthTech platform?
That's it for today!
The lab, the exam room and the operating theater have different needs, but today's stories ask the same practical question: can better integration make the work of care easier? Agilent is pursuing a closer connection between pathology hardware and software. Suki is bringing chart context and evidence into one interface. OTTAVA is moving from authorization toward commercial use.
The next test is what happens when teams use these systems every day. How much time do they save after training, review and maintenance are counted, and does that translate into better care? That is where a compelling platform story becomes a useful healthcare product.
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal